10,966 Shares in Globus Medical, Inc. (NYSE:GMED) Bought by Guggenheim Capital LLC

Guggenheim Capital LLC bought a new position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,966 shares of the medical device company's stock, valued at approximately $907,000.

Several other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in Globus Medical during the 4th quarter worth about $27,000. UMB Bank n.a. boosted its holdings in shares of Globus Medical by 60.2% during the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company's stock worth $45,000 after acquiring an additional 206 shares during the period. V Square Quantitative Management LLC grew its holdings in Globus Medical by 52.0% in the 4th quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company's stock valued at $48,000 after buying an additional 197 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Globus Medical by 24.7% in the 4th quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company's stock valued at $55,000 after purchasing an additional 132 shares during the period. Finally, Huntington National Bank boosted its stake in shares of Globus Medical by 47.8% in the fourth quarter. Huntington National Bank now owns 958 shares of the medical device company's stock valued at $79,000 after buying an additional 310 shares during the period. Institutional investors own 95.16% of the company's stock.

Globus Medical Stock Down 0.1 %

GMED traded down $0.05 during trading on Tuesday, hitting $72.57. 69,017 shares of the company traded hands, compared to its average volume of 1,036,755. The firm has a market cap of $9.98 billion, a P/E ratio of 96.64, a price-to-earnings-growth ratio of 1.61 and a beta of 1.28. The stock's fifty day moving average is $74.07 and its 200 day moving average is $80.17. Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93.

Globus Medical (NYSE:GMED - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million during the quarter, compared to analyst estimates of $646.19 million. On average, equities research analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of Globus Medical from $92.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their target price on shares of Globus Medical from $92.00 to $101.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. Bank of America upgraded Globus Medical from an "underperform" rating to a "neutral" rating and upped their price target for the company from $80.00 to $97.00 in a research report on Thursday, January 9th. Needham & Company LLC reissued a "hold" rating on shares of Globus Medical in a research note on Tuesday, March 18th. Finally, Wells Fargo & Company dropped their price target on Globus Medical from $95.00 to $93.00 and set an "overweight" rating on the stock in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $96.91.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.